Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Tax Provisions (2016 - 2026)

Anika Therapeutics has reported Tax Provisions over the past 17 years, most recently at $235000.0 for Q1 2026.

  • Quarterly Tax Provisions rose 135.0% to $235000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $827000.0 through Mar 2026, down 86.56% year-over-year, with the annual reading at $672000.0 for FY2025, 88.92% down from the prior year.
  • Tax Provisions was $235000.0 for Q1 2026 at Anika Therapeutics, up from -$1.0 million in the prior quarter.
  • Over five years, Tax Provisions peaked at $8.2 million in Q4 2023 and troughed at -$1.7 million in Q1 2023.
  • The 5-year median for Tax Provisions is $100000.0 (2025), against an average of $995764.7.
  • Year-over-year, Tax Provisions plummeted 272.91% in 2022 and then surged 542.0% in 2024.
  • A 5-year view of Tax Provisions shows it stood at $6.6 million in 2022, then rose by 23.76% to $8.2 million in 2023, then crashed by 69.13% to $2.5 million in 2024, then crashed by 140.71% to -$1.0 million in 2025, then soared by 122.86% to $235000.0 in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Tax Provisions are $235000.0 (Q1 2026), -$1.0 million (Q4 2025), and $939000.0 (Q3 2025).